Bolognese JA - Search Results

1

Gastrointestinal medications and procedures in osteoarthritis patients treated with rofecoxib compared with nonselective NSAIDs.

Watson DJ, Harper SE, Zhao PL, Bolognese JA, Simon TJ. Watson DJ, et al. Among authors: bolognese ja. MedGenMed. 2001 Nov 16;3(4):6. MedGenMed. 2001. PMID: 11965201 Free article.

2

The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis.

Watson DJ, Yu Q, Bolognese JA, Reicin AS, Simon TJ. Watson DJ, et al. Among authors: bolognese ja. Curr Med Res Opin. 2004 Oct;20(10):1539-48. doi: 10.1185/030079904x3078. Curr Med Res Opin. 2004. PMID: 15462687

3

Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis.

Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ. Watson DJ, et al. Among authors: bolognese ja. Arch Intern Med. 2000 Oct 23;160(19):2998-3003. doi: 10.1001/archinte.160.19.2998. Arch Intern Med. 2000. PMID: 11041909

4

Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs.

Watson DJ, Bolognese JA, Yu C, Krupa D, Curtis S. Watson DJ, et al. Among authors: bolognese ja. Curr Med Res Opin. 2004 Dec;20(12):1899-908. doi: 10.1185/030079904X12681. Curr Med Res Opin. 2004. PMID: 15701208

5

Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.

Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ. Langman MJ, et al. Among authors: bolognese ja. JAMA. 1999 Nov 24;282(20):1929-33. doi: 10.1001/jama.282.20.1929. JAMA. 1999. PMID: 10580458

6

The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis.

Ramey DR, Watson DJ, Yu C, Bolognese JA, Curtis SP, Reicin AS. Ramey DR, et al. Among authors: bolognese ja. Curr Med Res Opin. 2005 May;21(5):715-22. doi: 10.1185/030079905x43686. Curr Med Res Opin. 2005. PMID: 15974563

7

A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group.

Laine L, Harper S, Simon T, Bath R, Johanson J, Schwartz H, Stern S, Quan H, Bolognese J. Laine L, et al. Gastroenterology. 1999 Oct;117(4):776-83. doi: 10.1016/s0016-5085(99)70334-3. Gastroenterology. 1999. PMID: 10500058 Clinical Trial.

8

Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis.

Ehrich EW, Davies GM, Watson DJ, Bolognese JA, Seidenberg BC, Bellamy N. Ehrich EW, et al. Among authors: bolognese ja. J Rheumatol. 2000 Nov;27(11):2635-41. J Rheumatol. 2000. PMID: 11093446 Clinical Trial.

9

Effect of rofecoxib therapy on measures of health-related quality of life in patients with osteoarthritis.

Ehrich EW, Bolognese JA, Watson DJ, Kong SX. Ehrich EW, et al. Among authors: bolognese ja. Am J Manag Care. 2001 Jun;7(6):609-16. Am J Manag Care. 2001. PMID: 11439734 Free article. Clinical Trial.

10

A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects.

Hunt RH, Bowen B, Mortensen ER, Simon TJ, James C, Cagliola A, Quan H, Bolognese JA. Hunt RH, et al. Among authors: bolognese ja. Am J Med. 2000 Aug 15;109(3):201-6. doi: 10.1016/s0002-9343(00)00470-8. Am J Med. 2000. PMID: 10974182 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

76 results

Search Page

Filters